Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis
Open Access
- 12 November 2009
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 50 (12), 2033-2041
- https://doi.org/10.2967/jnumed.109.066993
Abstract
We have previously shown that, in vitro, monoclonal antibodies (mAbs) labeled with the Auger electron emitter 125I are more cytotoxic if they remain at the cell surface and do not internalize in the cytoplasm. Here, we assessed the in vivo biologic efficiency of internalizing and noninternalizing 125I-labeled mAbs for the treatment of small solid tumors. Methods: Swiss nude mice bearing intraperitoneal tumor cell xenografts were injected with 37 MBq (370 MBq/mg) of internalizing (anti-HER1) 125I-m225 or noninternalizing (anti-CEA) 125I-35A7 mAbs at days 4 and 7 after tumor cell grafting. Nonspecific toxicity was assessed using the irrelevant 125I-PX mAb, and untreated controls were injected with NaCl. Tumor growth was followed by bioluminescence imaging. Mice were sacrificed when the bioluminescence signal reached 4.5 × 107 photons/s. Biodistribution analysis was performed to determine the activity contained in healthy organs and tumor nodules, and total cumulative decays were calculated. These values were used to calculate the irradiation dose by the MIRD formalism. Results: Median survival (MS) was 19 d in the NaCl-treated group. Similar values were obtained in mice treated with unlabeled PX (MS, 24 d) and 35A7 (MS, 24 d) or with 125I-PX mAbs (MS, 17 d). Conversely, mice treated with unlabeled or labeled internalizing m225 mAb (MS, 76 and 77 d, respectively) and mice injected with 125I-35A7 mAb (MS, 59 d) showed a significant increase in survival. Irradiation doses were comparable in all healthy organs, independently from the mAb used, whereas in tumors the irradiation dose was 7.4-fold higher with 125I-labeled noninternalizing than with internalizing mAbs. This discrepancy might be due to iodotyrosine moiety release occurring during the catabolism of internalizing mAbs associated with high turnover rate. Conclusion: This study indicates that 125I-labeled noninternalizing mAbs could be suitable for radioimmunotherapy of small solid tumors and that the use of internalizing mAbs should not be considered as a requirement for the success of treatments with 125I Auger electrons.Keywords
This publication has 42 references indexed in Scilit:
- Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroidsMolecular Cancer Therapeutics, 2008
- Enhanced Retention of the α-Particle-Emitting Daughters of Actinium-225 by Liposome CarriersBioconjugate Chemistry, 2007
- A Comparison Between Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis of Colonic Origin in RatsAnnals of Surgical Oncology, 2007
- Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium‐90‐labeled murine HMFG1 without improvement in overall survivalInternational Journal of Cancer, 2007
- Phase III Trial of Intraperitoneal Therapy With Yttrium-90–Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete RemissionJournal of Clinical Oncology, 2006
- Antibody-guided radiation therapy of cancerCancer and Metastasis Reviews, 2005
- Radiotargeting agents for cancer therapyExpert Opinion on Drug Delivery, 2005
- Radioimmunotherapy of small-volume disease of metastatic colorectal cancerCancer, 2002
- Human carcinoembryonic antigen cDNA expressed in rat carcinoma cells can function as target antigen for tumor localization of antibodies in nude rats and as rejection antigen in syngeneic ratsInternational Journal of Cancer, 1992
- Successful Radioimmuno-therapy for Lung Metastasis of Human Colonic Cancer in Nude MiceJNCI Journal of the National Cancer Institute, 1991